Abstracts by keywords: SHI routine data
Longitudinal analysis of psoriasis, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and chronic bowel disease
Course of the disease and use of medication in chronic inflammatory diseases in Germany
02.04.2023
In statutory health insurance (GKV), service billing is carried out almost exclusively electronically, with service providers (e.g. doctors) extensively documenting the treatment of their patients according to precisely defined rules and then making this data available to the health insurance companies for billing purposes. Based on this routine data, a volume of more than 200 billion euros is billed annually for the entire statutory health insurance [1]. The purpose of GKV routine data is to bill GKV services [2]. However, this data can also be used as secondary data for many other purposes, such as in the context of health services research. Since billing data is usually available without any time or financial effort, there is increasing interest in the use of GKV routine data due to the latest health care reforms [3-6] and the reports of the Expert Council in the Health Care System [7-10]. In order to be able to use GKV routine data for scientific analyses, it must be clarified how valid such a secondary database is. This study therefore examined the question of the extent to which the billing data available to the health insurance companies on the use of medication by their insured persons corresponds to the actual medication taken, which was known from primary data from a clinical study that had already been carried out.